Section Arrow
LYEL.NASDAQ
- Lyell Immunopharma Inc
Quotes are at least 15-min delayed:2026/07/19 17:42 EDT
Regular Hours
Last
 13.32
-0.57 (-4.10%)
Day High 
13.9 
Prev. Close
13.89 
1-M High
16.8 
Volume 
168.67K 
Bid
13
Ask
18.47
Day Low
13.06 
Open
13.15 
1-M Low
11.47 
Market Cap 
340.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.55 
20-SMA 13.61 
50-SMA 15.21 
52-W High 45 
52-W Low 9.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.62/-9.81
Enterprise Value
382.29M
Balance Sheet
Book Value Per Share
11.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.00K
Operating Revenue Per Share
1.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ATAIAtaiBeckley Inc7.22+0.07+0.98%-- 
JSPRJasper Therapeutics0.885+0.111+14.34%-- 
LIMNLiminatus Pharma Inc0.123-0.0247-16.72%-- 
IOVAIovance Biotherapeutics5+0.34+7.30%-- 
RXRXRecursion Pharmaceuticals2.945-0.075-2.48%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) andother GCC-expressing cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.